Potent anti-tumor killing activity of the multifunctional Treg cell line HOZOT against human tumors with diverse origins

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1299-1306

  Inoue, Toshiya ^a   Tashiro, Yuichi ^b   Takeuchi, Makoto ^a   Otani, Takeshi ^a   Tsuji Takayama, Kazue ^a   Okochi, Ayumi ^a   Mukae, Yuriko ^b   Koreishi, Mayuko ^b   Yamasaki, Fumiyuki ^c   Kumon, Hiromi ^b   Nakamura, Shuji ^a   Kibata, Masayoshi ^a   Kondo, Eisaku ^b,d  

^a HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c University of Tokyo   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cytotoxic treg; Immunotherapy; In vivo; NOD SCID mouse

Indexed keywords

CASPASE 3; CD1D ANTIGEN; CD8 ANTIGEN; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TWEAK PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CELL STRAIN HOZOT; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; FIBROBLAST; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MESOTHELIOMA; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; OSTEOSARCOMA; OVARY CARCINOMA; PERITONEUM; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STOMACH ADENOCARCINOMA; UTERINE CERVIX CARCINOMA;

ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; T-LYMPHOCYTES, REGULATORY;

EID: 79955016829     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.962     Document Type: Article

References (20)

1. Nakamura S, Suzuki M, Sugimoto A, et al: IL-2-independent generation of FOXP3(+)CD4(+)CD8(+)CD25(+) cytotoxic regulatory T cell lines from human umbilical cord blood. Exp Hematol 35: 287-296, 2007. (Pubitemid 46135820)
2. Leen AM, Rooney CM and Foster AE: Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265, 2007. (Pubitemid 46697909)
3. Kabelitz D, Wesch D and He W: Perspectives of gammadelta T cells in tumor immunology. Cancer Res 67: 5-8, 2007. (Pubitemid 46142752)
4. Terme M, Ullrich E, Delahaye NF, Chaput N and Zitvogel L: Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9: 486-494, 2008. (Pubitemid 351560517)
5. Taniguchi M, Harada M, Kojo S, Nakayama T and Wakao H: The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21: 483-513, 2003. (Pubitemid 37174539)
6. Ha TY: The role of regulatory T cells in cancer. Immune Netw 9: 209-235, 2009.
7. Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S: Functions of natural killer cells. Nat Immunol 9: 503-510, 2008. (Pubitemid 351560519)
8. Terabe M and Berzofsky JA: The role of NKT cells in tumor immunity. Adv Cancer Res 101: 277-348, 2008.
9. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP and Ley TJ: Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21: 589-601, 2004. (Pubitemid 39370513)
10. Zheng J, Liu Y, Qin G, et al: Efficient induction and expansion of human alloantigen-specific CD8 regulatory T cells from naive precursors by CD40-activated B cells. J Immunol 183: 3742-3750, 2009.
11. Tanaka J, Toubai T, Tsutsumi Y, et al: Cytolytic activity and regulatory functions of inhibitory NK cell receptor-expressing T cells expanded from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 104: 768-774, 2004. (Pubitemid 38970571)
12. Young KJ, DuTemple B, Phillips MJ and Zhang L: Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol 171: 134-141, 2003. (Pubitemid 36745281)
13. Otani T, Nakamura S, Inoue T, et al: Erythroblasts derived in vitro from embryonic stem cells in the presence of erythropoietin do not express the TER-119 antigen. Exp Hematol 32: 607-613, 2004. (Pubitemid 38891529)
14. Tsuji-Takayama K, Suzuki M, Yamamoto M, et al: The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J Immunol 181: 3897-3905, 2008.
15. Fukazawa T, Matsuoka J, Naomoto Y, Maeda Y, Durbin ML and Tanaka N: Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy. Cancer Res 68: 7120-7129, 2008.
16. Harashima A, Toraya T, Okochi A, et al: Interleukin-8 and RANTES are signature cytokines made by HOZOT, a new type of regulatory T cells. Mol Immunol 46: 3310-3319, 2009.
17. Suzuki M, Sugimoto A, Harashima A, et al: Novel mechanisms of suppressor activity exhibited by cytotoxic regulatory T cell lines, HOZOT. Exp Hematol 37: 92-100, 2009.
18. Verheul HM, Hoekman K, Jorna AS, Smit EF and Pinedo HM: Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5 (Suppl 1): 45-50, 2000. (Pubitemid 30225457)
19. Smith EM and Jayson GC: The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15: 59-72, 2003. (Pubitemid 36348121)
20. Takeuchi M, Inoue T, Otani T, Yamasaki F, Nakamura S and Kibata M: Cell-in-cell structures formed between human cancer cell lines and the cytotoxic regulatory T-cell line HOZOT. J Mol Cell Biol 2: 139-151, 2010.